Evidence map›Paper›PMID 37422474›Full record

ArticleScientific reports2023

Rapid screening of SARS-CoV-2 variants, a key tool for pandemic surveillance.

Irene Muñoz-Gallego, María Ángeles Meléndez Carmona, Carmen Martín Higuera, Esther Viedma, Rafael Delgado, María Dolores Folgueira

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Irene Muñoz-GallegoLaboratory of Virology, Microbiology Department, Hospital Universitario, 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain. iremunozg@gmail.com.
María Ángeles Meléndez CarmonaLaboratory of Virology, Microbiology Department, Hospital Universitario, 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
Carmen Martín HigueraLaboratory of Virology, Microbiology Department, Hospital Universitario, 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
Esther ViedmaLaboratory of Virology, Microbiology Department, Hospital Universitario, 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
Rafael DelgadoLaboratory of Virology, Microbiology Department, Hospital Universitario, 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
María Dolores FolgueiraLaboratory of Virology, Microbiology Department, Hospital Universitario, 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
Hospital Universitario 12 De Octubre · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The utility of reverse transcription-polymerase chain reaction (RT-PCR) in analysis SARS-COV-2 variants was evaluated. RT-PCR tests were used to analyse the majority of new SARS-CoV-2 cases (n = 9315) in a tertiary hospital (Madrid, Spain) throughout 2021. Subsequently, whole genome sequencing (WGS) was conducted on 10.8% of these samples (n = 1002). Notably, the Delta and Omicron variants emerged rapidly. There were no discrepancies between RT-PCR and WGS results. Continuous surveillance of SARS-CoV-2 variants is essential, and RT-PCR is a highly useful method, specially during periods of high COVID-19 incidence. This feasible technique can be implemented in all SARS-CoV-2 laboratories. However, WGS remains the gold standard method for comprehensive detection of all existing SARS-CoV-2 variants.

Indexed as

COVID-19SARS-CoV-2HumansLaboratoriesPandemics

Identifiers

PMID37422474
PMCPMC10329708
OpenAlexW4383618809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.